### Supplementary Table 2. Comparison of with or without HCC before DAA therapy in genotype 2 patients

| Variable                  | Row data                  | Propensity score matching | p value | Row data                  | Propensity score matching | p value |
|---------------------------|---------------------------|---------------------------|---------|---------------------------|---------------------------|---------|
|                           | Without HCC (n = 77)      | With HCC (n = 8)          |         | Without HCC (n = 18)      | With HCC (n = 8)          |         |
|                           |                           |                           |         |                           |                           |         |
| Age, yr                   | 58.0 (54.0–64.0)          | 76.5 (69.0–80.0)          | 0.001   | 69.8 (63.0–76.0)          | 76.5 (69.0–80.0)          | 0.085   |
| Female sex                | 49 (63.6)                 | 1 (12.5)                  | 0.007   | 8 (44.4)                  | 1 (12.5)                  | 0.192   |
| BMI                       | 22.5 (21.1–24.9)          | 22.8 (22.2–23.9)          | 0.845   | 23.6 (20.6–25.4)          | 22.8 (22.2–23.9)          | 0.964   |
| HCV-RNA                   | 754,000.0 (111,000.0–3,390,000.0) | 93,600.0 (71,200.0–819,000.0) | 0.134   | 331,000.0 (18,500.0–2,240,000.0) | 93,600.0 (71,200.0–819,000.0) | 0.934   |
| SVR 12                    | 74 (96.1)                 | 7 (87.5)                  | 0.332   | 15 (83.3)                 | 7 (87.5)                  | 1.000   |
| Prior IFN experienced     | 12 (15.6)                 | 4 (50.0)                  | 0.038   | 2 (11.1)                  | 4 (50.0)                  | 0.051   |
| Liver cirrhosis           | 22 (28.6)                 | 8 (100.0)                 | 0.001   | 6 (33.3)                  | 8 (100.0)                 | 0.002   |
| CTP score                 |                           |                           | 0.563   |                           |                           | 1.000   |
| A                         | 70 (90.9)                 | 7 (87.5)                  |         | 15 (93.7)                 | 7 (87.5)                  |         |
| B                         | 3 (3.9)                   | 1 (12.5)                  |         | 1 (6.3)                   | 1 (12.5)                  |         |
| MELD-NA score             |                           |                           | 0.016   |                           |                           | 0.026   |
| < 9                       | 56 (82.4)                 | 3 (37.5)                  |         | 13 (86.7)                 | 3 (37.5)                  |         |
| 10–19                     | 11 (16.2)                 | 4 (50.0)                  |         | 2 (13.3)                  | 4 (50.0)                  |         |
| 20–29                     | 1 (1.5)                   | 1 (12.5)                  |         | 0                        | 1 (12.5)                  |         |

Values are presented as median (interquartile range) or number (%).

HCC, hepatocellular carcinoma; DAA, direct-acting antiviral; BMI, body mass index; HCV-RNA, hepatitis C virus ribonucleic acid; SVR 12, sustained viral response at 12 weeks; IFN, interferon; CTP, Child-Turcotte-Pugh; MELD-NA, model for end-stage liver disease with incorporation of serum sodium.